Economic implications of nonadherence to highly active antiretroviral treatment in HIV patients

Bibliography

• CHESNEY MA, MORIN M, SHERR L: Adherence to HIV combination therapy. Soc. Sci. Med. (2000) 50(11):1599-1605.
   PubMed Web of Science ®Google Scholar
• SHERR L: Adherence-sticking to the evidence. AIDS Care (2000) 12:373-375.
   PubMed Web of Science ®Google Scholar
• HAUBRICH RH, LITTLE SJ, CURRIER JS et al.: The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS (1999) 13:1099-1107.
   PubMed Web of Science ®Google Scholar
• BANGSBERG DR, HECHT FM, CHARLEBOIS ED et al.: Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 14:357-366.
   PubMed Web of Science ®Google Scholar
• PATERSON DL, SWINDELLS S et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133:21-30.
   PubMed Web of Science ®Google Scholar
• BANGSBERG DR, PERRY S, CHARLEBOIS ED et al.: Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (2001) 15:1181-1183.
   PubMed Web of Science ®Google Scholar
• GARCIA DE OLALLA P, KNOBEL H, CARMONA A, GUELAR A, LOPEZ-COLOMES JL, CAYLA JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J. Acquir. Immune Defic. Syndr. (2002) 30:105-110.
   PubMed Web of Science ®Google Scholar
• CARRIERI MP, RAFFI F, LEWDEN C et al.: Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3 year follow-up study. Antivir. Ther. (2003) 8:37-46.
   PubMed Web of Science ®Google Scholar
• SMITH PF, DICENZO R, MORSE GD: Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. (2001) 40:893-905.
   PubMed Web of Science ®Google Scholar
• JOLY V, YENI P: Non-nucleoside reverse transcriptase inhibitors. Ann. Med. Intern (2000) 15:260-267.
   Google Scholar
• MANGUM EM, GRAHAM KK: Lopinavir-ritonavir: a new protease inhibitor. Pharmacotherapy (2001) 21:1352-1363.
   PubMed Web of Science ®Google Scholar
• KATZENSTEIN DA: Adherence as a particular issue with protease inhibitors. J. Assoc. Nurses AIDS Care (1997) 8:10-17.
   PubMedGoogle Scholar
• BANGSBERG DR, CHARLEBOIS ED, GRANT RM et al.: High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 17:1925-1932.
   PubMed Web of Science ®Google Scholar
• WALSH JC, POZNIAK AL, NELSON MR, MANDALIA S, GAZZARD BG: Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J. Acquir. Immune Defic. Syndr. (2002) 30:278-287.
   PubMed Web of Science ®Google Scholar
• CINGOLANI A, ANTINORI A, RIZZO MG et al.: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (2002) 16:369-379.
   PubMed Web of Science ®Google Scholar
• SETHI AK, CELENTANO DD, GANGE SJ, MOORE RD, GALLANT JE: Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. (2003) 37:1112-1118.
   PubMed Web of Science ®Google Scholar
• CARRIERI P, CAILLETON V, LE MOING V et al.: The dynamic of adherence to highly active antiretroviral therapy: results from the french national APROCO cohort. J. Acquir. Immune Defic. Syndr. (2001) 28:232-239.
   PubMed Web of Science ®Google Scholar
• HOWARD AA, ARNSTEN JH, LO Y et al.: A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 16:2175-2182.
   PubMed Web of Science ®Google Scholar
• TESORIERO J, FRENCH T, WEISS L, WATERS M, FINKELSTEIN R, AGINS B: Stability of adherence to highly active antiretroviral therapy over time among clients enrolled in the treatment adherence demonstration project. J. Acquir. Immune Defic. Syndr. (2003) 33:484-493.
   PubMed Web of Science ®Google Scholar
• HERTOGS K, BLOOR S, KEMP SD et al.: Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS (2000) 14:1203-1210.
   PubMed Web of Science ®Google Scholar
• HAYNES R, MCKIBBON K, KANANI R: Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet (1996) 100:258-268.
   Google Scholar
• LERNER B, GULICK R, DUBLER N: Rethinking non-adherence: historical perspectives on triple-drug therapy for HIV disease. Ann. Intern. Med. (1998) 129:573-578.
   PubMed Web of Science ®Google Scholar
• SPIRE B, DURAN S, SOUVILLE M, LEPORT C, RAFFI F, MOATTI JP: Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc. Sci. Med. (2002) 54:1481-1496.
   PubMed Web of Science ®Google Scholar
• DURAN S, SPIRE B, RAFFI F et al.: Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin. Trials (2001) 2:38-45.
   PubMedGoogle Scholar
• AMMASSARI A, MURRI R, PEZZOTTI P et al.: Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J. Acquir. Immune Defic. Syndr. (2001) 28:445-449.
   PubMed Web of Science ®Google Scholar
• ICKOVICS JR, CAMERON A, ZACKIN R et al.: Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir. Ther. (2002) 7:185-193.
   PubMed Web of Science ®Google Scholar
• DURAN S, SAVES M, SPIRE B et al.: Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS (2001) 15:2441-2444.
   PubMed Web of Science ®Google Scholar
• CARRIERI P, SPIRE B, DURAN S et al.: Health-related quality of life after 1 year of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2003) 32:38-47.
   PubMed Web of Science ®Google Scholar
• NIEUWKERK PT, GISOLF EH, COLEBUNDERS R, WU AW, DANNER SA, SPRANGERS MA : Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy: the Prometheus Study Group. AIDS (2000) 14:181-187.
   PubMed Web of Science ®Google Scholar
• TULDRA A, FUMAZ CR, FERRER MJ et al.: Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2000) 25:221-228.
   PubMed Web of Science ®Google Scholar
• PRADIER C, BENTZ L, SPIRE B et al.: Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French Prospective Controlled Study. HIV Clin. Trials (2003) 4:121-131.
   PubMed Web of Science ®Google Scholar
• GOUJARD C, BERNARD N, SOHIER N et al.: Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J. Acquir. Immune Defic. Syndr. (2003) 34:191-194.
   PubMed Web of Science ®Google Scholar
• FREEDBERG KA, LOSINA E, WEINSTEIN MC et al.: The cost effectiveness of combination antiretroviral therapy for HIV infection. N. Engl. J. Med. (2001) 344:824-831.
   PubMed Web of Science ®Google Scholar
• VALENTI WM: HAART is cost-effective and improves outcomes. AIDS Reader (2001) 11:260-262.
   PubMedGoogle Scholar
• BOZZETTE SA, JOYCE G, MCCAFFREY DF et al.: Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N. Engl. J. Med. (2001) 344:817-823.
   PubMed Web of Science ®Google Scholar
• CLEEMPUT I, KESTELOOT, DEGEEST S: A review of the literature on the economics of non compliance: room for methodological improvement. Health Policy (2002) 59:65-94.
   PubMed Web of Science ®Google Scholar
• HUGHES DA, BAGUST A, HAYCOX A, WALLEY T: The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ. (2001) 10:601-615.
   PubMed Web of Science ®Google Scholar
• ELLIOTT RA, BARBER N: Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann. Pharmacother. (2005) 39(3):508-515.
   PubMed Web of Science ®Google Scholar
• RIZZO JA, SIMONS WR: Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin. Ther. (1997) 19:1446-57
   PubMed Web of Science ®Google Scholar
• MCCOMBS JS, NICHOL MB, NEWMAN CM, SCLAR DA: The cost of interrupting antihypertensive drug therapy in a Medicaid population. Med. Care (1994) 32:214-226.
   PubMed Web of Science ®Google Scholar
• GOLAN L, BIRKMEYER JD, WELCH HG: The cost-effectiveness of treating all patients Type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann. Intern. Med. (1999) 131:707-708.
   PubMed Web of Science ®Google Scholar
• LAFATA JE, MARTIN SA, KAATZ S, WARD RE: The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J. Gen. Intern. Med. (2000) 15:31-37.
   PubMed Web of Science ®Google Scholar
• TAYLOR JL, ZAGARI M, MURPHY K, FRESTON JW: Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch. Intern. Med. (1997) 157:87-97.
   PubMedGoogle Scholar
• BROWN RE, KENDALL MJ, HALPERN MT: Cost analysis of once-daily ISMN versus twice-daily ISMN or transdermal patch for nitrate prophylaxis. J. Clin. Pharm. Ther. (1997) 22:67-76.
   PubMed Web of Science ®Google Scholar
• GENC M, MARDH PA: Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis. Pharmacoeconomics (1997) 12:374-383.
   PubMed Web of Science ®Google Scholar
• LAPIERRE Y, BENTKOVER J, SCHAINBAUM S, MANNERS S: Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada. Can. J. Psychiatry (1995) 40:370-377.
   PubMed Web of Science ®Google Scholar
• ROCCHI A, TINGEY D: Economic evaluation of dorzolamide versus pilocarpine for primary open-angle glaucoma. Can. J. Ophtalmol. (1997) 32:414-418.
   PubMed Web of Science ®Google Scholar
• GLAZER WM, ERESHEFSKY L: A pharmacoeconomic model of outpatient antipsychotic therapy in revolving door schizophrenic patients. J. Clin. Psychiatry (1996) 57:337-345.
   PubMed Web of Science ®Google Scholar
• BILLUPS SJ, MALONE DC, CARTER BL: The relationship between drug therapy non-compliance and patient characteristics, health-related quality of life and health care costs. Pharmacotherapy (2000) 20:941-949.
   PubMed Web of Science ®Google Scholar
• HADDIX AC, HILLIS SD, KASSLER WJ: The cost-effectiveness of azithromycin for chlamdia trachomatis infections in women. Sex. Trans. Dis. (1995) 22:274-280.
   PubMed Web of Science ®Google Scholar
• SCOTT LL, ALEXANDER J: Cost-effectiveness of acyclovir suppression to prevent prevent recurrent genital herpes in term pregnancy. Am. J. Perinatol. (1998) 15:57-62.
   PubMed Web of Science ®Google Scholar
• BROWN MCJ, NIMMERRICHTER AA, GUEST JF: Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria. Eur. Psychiatry (1999) 14:230-244.
   PubMed Web of Science ®Google Scholar
• GARTON MJ, COOPER C, REID D: Perimenopausal bone density screening - will it help prevent osteoporosis? Maturitas (1997) 26:35-43.
   PubMed Web of Science ®Google Scholar
• KOBELT G, JONSSON L, MATTIASSON A: Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol. Urodyn. (1998) 17:599-611.
   PubMed Web of Science ®Google Scholar
• REVICKI DA, BROWN RE, KELLER MB, GONZALES J, CULPEPPER L, HALES RE: Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J. Clin. Psychiatry (1997) 58:47-58.
   PubMed Web of Science ®Google Scholar
• CLARK WF, CHURCHILL DN, FORWELL L, MACDONALD G, FOSTER S: To pay or not to pay ? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor for diabetic nephropathy. Can. Med. Ass. (2000) 162:195-198.
   PubMed Web of Science ®Google Scholar
• DRUMMOND MF, O’BRIEN B, STODDARD GL, TORRANCE GW: Methods for the Economics Evaluation of Health Care Programmes. Oxford University Press, Oxford (1997).
   Google Scholar
• KAUF TL, JORDAN J: The cost-effectiveness of adherence. AIDS (2000) 14:S102-S102.
   Web of Science ®Google Scholar
• STRINGER JSA, DWIGHT JR, VERMUND SH, GOLDENBERG RL, SINKALA M, STINNETT AA: Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa. J. Acquired Immune Def. Syn. (2000) 24:369-377.
   PubMed Web of Science ®Google Scholar
• SCALERA A, BAYOUMI AM, OH PI, RISEBROUGH N, SHEAR NH, TSENG A: Clinical and economic implications of non-adherence to HAART in HIV infection. Disease Management and Health Outcomes (2002) 10(2):85-89.
   Google Scholar
• STANSELL J, BARRETT J, DEGUZMAN C et al.: Incremental costs of HIV suppression in HIV therapeutic failure. Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2000) Abstr. 761.
   Google Scholar
• GOLDIE SJ, PALTIEL AD, WEINSTEIN MC et al.: Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am. J. Med. (2003) 115(8):632-641.
   PubMed Web of Science ®Google Scholar
• ZARIC GS, BAYOUMI A, BRANDEAU ML, OWENS DK: Cost-Effectiveness of improved adherence to antiretroviral therapy. Value in Health (2003) 6(3):266.
   Google Scholar
• LAMIRAUD K, GEOFFARD PY: Therapeutic non adherence: a rational behaviour revealing patient preferences? Working paper Institute of Health Economics and Management (IEMS), Lausanne (2004).
   Google Scholar
• JOHNSTON-ROBERTS, MANN T: Adherence to antiretroviral medications in HIV/AIDS care: a narrative exploration of one woman’s foray into intentional non adherence. Health Care for Women International (2003) 24:552-564.
   PubMedGoogle Scholar
• BECKER MH, MAIMAN LA: Sociobehavioural determinants of compliance with health care and medical care recommendation. Med. Care (1975) 13:10-24.
   PubMed Web of Science ®Google Scholar
• FISHBEIN M, AJZEN: Belief, attitude, intention and behaviour: an introduction to theory and research. Addison-Wesley, Don Mills, NY (1975).
   Google Scholar
• CORONARY DRUG PROJECT: Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N. Engl. J. Med. (1980) 303:1038-1041.
   PubMed Web of Science ®Google Scholar
• IRVINE J, BAKER B, SMITH J et al.: Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhytmia Trial. Psychosom. Med. (1999) 61:566-575.
   PubMed Web of Science ®Google Scholar
• HORWITZ RI, VISCOLI CM, BERKMAN L et al.: Treatment adherence and risk of death after a myocardial infarction. Lancet (1990) 336:542-545.
   PubMed Web of Science ®Google Scholar
• GALLAGHER EJ, VISCOLI CM, HORWITZ RI: The relationship of treatment adherence to the risk of dealth after myocardial infarction in women. JAMA (1993) 270:742-744.
   PubMed Web of Science ®Google Scholar
• BOZZETTE SA, GIFFORD AL: The economic viability of antiretroviral adherence interventions. Am. J. Med. (2003) 115(8):672-673.
   PubMed Web of Science ®Google Scholar
• LUCE BR, ELIXHAUSER A: Estimating costs in economic evaluation of medical technologies. Int. J. Technol. Assess. Health Care (1990) 6:57-75.
   PubMedGoogle Scholar
• PROTIÈRE C, DONALDSON C, LUCHINI S, MOATTI JP, SHACKLEY P: The impact of information on non-health attributes on willingness to pay for multiple health care programmes. Soc. Sci. Med. (2004) 58:1257-1269.
   PubMed Web of Science ®Google Scholar
• CLARKE PM: Cost-benefit analysis and mammographic screening: a travel cost approach. J. Health Econ. (1996) 17:767-787.
   Web of Science ®Google Scholar